BSG and neoplasm: To evaluate the systemic toxicity of CD147-CAR-NK therapy in a cell-line-derived xenograft (CDX) HCC tumor model, we treated tumor-bearing hCD147TG NSG and tumor-bearing wild-type (WT) NSG mice with three doses of CD147-CAR-NK therapy at different time points (Figure 2A).